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Abstract  1 
 Youth type 2 diabetes (T2D) is increasing, linked with obesity and declining physical 2 
activity in high-risk populations. Recent multi-center studies have led to tremendous advances in 3 
our understanding of the epidemiology, pathophysiology, diagnosis, treatment and complications 4 
of this condition. As in adult T2D, youth T2D is associated with insulin resistance, together with 5 
progressive deterioration in β cell function and relative insulin deficiency in the absence of 6 
diabetes-related immune markers. However, increasing obesity in children with type 1 diabetes 7 
(T1D) blurs the clinical distinction between youth T2D and autoimmune-mediated T1D.  In stark 8 
contrast to adult T2D, the decline in β cell function is 3-4 fold faster in youth T2D and 9 
therapeutic failure rates in youth are significantly higher than in adults. Whether or not the more 10 
aggressive nature of youth T2D is driven by genetic heterogeneity or by physiology/metabolic 11 
maladaptation is yet unknown.  The lack of approved pharmaco-therapeutic agents for youth 12 
T2DM, besides metformin, targeting the pathophysiological mechanisms is a major barrier to 13 
optimal diabetes management.  There is a desperate need for effective therapeutic options, in 14 
addition to prevention, to halt the projected four-fold increase in youth T2D by 2050 and its 15 
consequences of heightened diabetes morbidity and mortality at younger ages.   16 
  17 
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Introduction 1 
Diabetes mellitus (DM) is a disorder characterized by hyperglycemia resulting from 2 
defects in insulin action and/or production. The most common form of DM in youth is immune-3 
mediated type 1A diabetes (T1D) resulting from  autoimmune insulitis and destruction of the 4 
pancreatic β-cells,  leading to  absolute insulin deficiency.
1
 Diabetes-associated pancreatic 5 
autoantibodies are present in over 90% of youth with T1D at the time of diagnosis.
2
 The 6 
traditional text-book description of childhood T1D is that of a normal-weight child who develops 7 
polyuria, polydipsia, and nocturia which progressively worsens resulting in weight loss, ketosis, 8 
dehydration and ultimately diabetic ketoacidosis if unrecognized and untreated in a timely 9 
fashion.
3
     10 
In contrast, type 2 diabetes (T2D) in youth, an increasingly recognized pediatric disorder 11 
of the millennium, is primarily associated with insulin resistance together with β-cell dysfunction 12 
and relative insulin deficiency
4-7
, and the absence of circulating diabetes-related immune 13 
markers.
8, 9
 Globally, T2D accounts for around 90% of all cases of diabetes, but predominantly 14 
effects adults.
10, 11
 T2D was rare in youth, but with the soaring trajectory of childhood obesity, 15 
T2D is now being diagnosed in an ever increasing number of youth.
12
 The text-book description 16 
of youth T2D is that of an overweight and/or obese adolescent, in mid-puberty, with 17 
overrepresentation of minority ethnicity/racial groups and females.
13
 These adolescents could be 18 
totally asymptomatic and/or minimally symptomatic, diagnosed incidentally during a routine 19 
checkup, or could present with significant symptoms of hyperglycemia, weight loss, metabolic 20 
decompensation and even ketoacidosis.
5
     21 
Obesity is the hallmark of T2D in North American youth.
13
 However, with the escalating 22 
rates of obesity in the general population, children with autoimmune T1D are also becoming 23 
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overweight/obese making the clinical distinction between T2D and obese T1D difficult.
14-16
 In 1 
this review, we present important lessons learned from studies which have led to significant 2 
advances in our understanding of the epidemiology, pathophysiology, diagnosis, treatment and 3 
complications of T2D in youth. We will offer current-day knowledge comparing and contrasting 4 
T2D with T1D in youth, and adult T2D with youth T2D. Recent multi-center studies of T2D in 5 
youth referred to throughout this review are introduced briefly here.   6 
 7 
Key Multi-Center Studies of T2D in Youth 8 
The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) is an 9 
ongoing study funded by the National Institute of Diabetes and Digestive and Kidney Diseases 10 
(NIDDK).
17
 TODAY was a nationwide randomized clinical trial to compare three different 11 
interventions for the treatment of T2D in youth:  metformin alone, metformin plus intensive 12 
lifestyle intervention, and metformin plus rosiglitazone. Participants with T2D were recruited 13 
over 4 years at 15 clinical centers in the United States (n=704) and enrolled, randomized, treated, 14 
and followed up for 2-6 years, with a mean duration of therapy of 3.9 years. Participants had to 15 
have a BMI ≥85
th
 percentile for age and gender, be negative for two islet autoantibodies, 16 
glutamic acid decarboxylase (GAD) and insulinoma-associated protein-2 (IA2), and have an 17 
adult family member willing to participate with them. The primary outcome was time to 18 
treatment failure, or loss of glycemic control defined as sustained elevation in HbA1c ≥8% for 6 19 
months, or the inability to wean from temporary insulin therapy within 3 months following acute 20 
metabolic decompensation. The TODAY results advanced our understanding about the treatment 21 
of youth T2D, the natural history of β-cell failure and insulin sensitivity, the predictors of 22 
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glycemic failure, the complications of youth T2D and rates of progression, all to be discussed 1 
below.     2 
The SEARCH for Diabetes in Youth study 3 
(www.serchfordiabetes.org/public/dsphome.cfm) is an ongoing, national, population-based, 4 
multi-center study, funded by the U.S. Centers for Disease Control and Prevention (CDC) and 5 
the NIDDK, aimed at understanding the epidemiology and outcomes of both T1D and T2D in 6 
youth and young adults.  It was initiated in 2000 and has 5 primary participating centers. The 7 
SEARCH has been a principle source of information regarding the prevalence and incidence of 8 
T1D and T2D in U.S. youth of diverse racial/ethnic backgrounds. SEARCH has been 9 
instrumental in advancing our understanding of the burden of diabetes-related complications in 10 
youth, with important implications for ongoing health, quality of life, as well as economic 11 
implications.
12, 18-20
    12 
The HEALTHY study was funded by the NIDDK with additional support from the 13 
American Diabetes Association (ADA).
21
 The objective of the HEALTHY study was to decrease 14 
risk factors for T2D in youth during middle school via a school-based intervention targeting 15 
nutrition, physical education, changing behaviors, and social marketing to increase visibility of 16 
the program within participating schools. The study involved a collaborative group of 17 
institutions, 42 middle schools (21 intervention and 21 control schools), and followed students 18 
prospectively from the start of 6
th
 grade to the end of 8
th
 grade. The primary outcome was the 19 
percent of students with a BMI ≥85
th
 percentile in the intervention versus control schools at the 20 
end of 8
th
 grade. Although the comprehensive school-based intervention did not result in greater 21 
decreases in the proportion of students with a BMI ≥85
th
 percentile, it clarified the significant 22 
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prevalence of risk factors for T2D in a targeted population, and did result in significant 1 
reductions in indices of adiposity among obese participants.
22, 23
  2 
 3 
Epidemiology of Youth T2D  4 
Globally, approximately 347 million people have diabetes, the majority of whom are 5 
adults with T2D.
24
 Among youth, T1D is much more prevalent than T2D. Worldwide, it is 6 
estimated that nearly 500,000 children and adolescents are living with T1D, and nearly 80,000 7 
youth under the age of 15 years develop T1D annually.
25
 In the U.S., according to the 2014 8 
National Diabetes Statistics Report, an estimated 208,000 youth under the age of 20 years have 9 
been diagnosed with diabetes (0.25% prevalence rate or approximately 1 in 400 children).
26
 The 10 
incidence of T1D among youth is increasing in many countries, with the overall annual increase 11 
estimated to be ∼2.5-4% in the past decade.
12, 27-29
 In 2012, the annual incidence of diagnosed 12 
diabetes in U.S. youth was estimated to be 18,436 for T1D and 5,089 for T2D.
26
     13 
As compared with T1D, information is sparse with regard to the global prevalence and 14 
incidence of T2D among youth. A recent systematic review demonstrated that the worldwide 15 
incidence and prevalence of T2D in youth vary substantially among countries, age categories and 16 
ethnic groups, caused by both population characteristics and methodological differences.
30
 In the 17 
US, in the late 1970’s it was documented that obese Pima Indian youth with strong family 18 
histories of T2D were developing the disease.
31
 As childhood obesity increased, so has the 19 
prevalence of T2D in youth over the age of 10 years.
32, 33
 Diagnosed T2D among youth was 20 
documented in 4 geographic areas and 1 managed health care plan in the U.S. from 2001 to 2009 21 
by the SEARCH for Diabetes in Youth study (Table 1).
12
 The prevalence of T2D was 0.46 per 22 
1,000 youth aged 10-19 years (0.046%), significantly lower than the prevalence of T1D (1.93 per 23 
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1,000 children aged 0-19 years; 0.193%). The prevalence varied by race/ethnicity and was 1 
highest in American Indians (0.120%), followed by black (0.106%), Hispanic (0.079%), Asian 2 
Pacific Islander (0.034%), and white youth (0.017%). Females are predominantly effected 3 
(0.058% versus 0.035% in males). This is in contrast with T1D, where there is no gender 4 
differential and white youth are predominantly effected.
12
 Between 2001 and 2009, the 5 
prevalence of T2D in youth increased by approximately 30%, while the prevalence of T1D 6 
increased by around 23%.
12
 Projections of T2D burden in the US population aged < 20 years 7 
from 2010 through 2050, forecast an increase from 20,203 to 30,111 cases assuming a constant 8 
incidence over time.
34
 On the other hand, modeling the projections based on a yearly 2.3% 9 
increase across all ages almost quadruples the number of youth with T2D from 22,820 in 2010 to 10 
84,131 in 2050:. A prevalence increase from 0.27/1,000 to 0.75/1,000 (+178% increase).
34
          11 
While factors promoting the increasing prevalence of T1D are not understood, increasing 12 
rates of T2D are linked with the obesogenic environment of developed countries, nutritional 13 
excesses and rapid increases in obesity, together with declining physical activity in high-risk 14 
populations. Concurrently, increasing obesity among youth with T1D is clouding the clinical 15 
distinction between the two conditions.
14-16
 Thus, some reports of increasing rates of T2D may 16 
be muddled by including obese T1D youth as having T2D. This was illustrated in the TODAY 17 
study in which all enrolled participants with a clinical diagnosis of T2D were screened for 18 
circulating GAD-65 and IA2 antibodies using standardized assays.
35
  Of the 1,206 youth 19 
screened and clinically considered to have T2D, 118 (9.8%) were antibody positive, 5.9% were 20 
positive for a single antibody and 3.9% were positive for both antibodies, making them  21 
ineligible for TODAY. In smaller scale studies the reported rates of positive pancreatic 22 
autoantibodies in youth clinically diagnosed with T2D vary from 10 to 75%.
36-41
  23 
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The transition from normal glucose tolerance to overt T2D is characterized by an 1 
intermediate state of prediabetes indicative of the relatively high risk for the future development 2 
of T2D.
42
 Individuals with prediabetes are defined as having impaired fasting glucose (IFG) 3 
[fasting plasma glucose levels 100 mg/dl to 125 mg/dl], or impaired glucose tolerance (IGT) [2-4 
hr glucose values in the oral glucose tolerance test (OGTT) of 140 mg/dl to 199 mg/dl].
42
   5 
Among U.S. adolescents 12-19 years of age the prevalences of IFG, IGT and prediabetes were 6 
13.1, 3.4 and 16.1%, respectively.
43
 Overweight adolescents had a 2.6-fold higher rate than those 7 
with normal weight.
43
 The prevalence is even higher (up to 25%) among obese adolescents 8 
referred to tertiary obesity treatment centers.
44, 45
 In the HEALTHY study of middle-school 9 
students (n=6,358), 40.5% of the participants had IFG and the mean FPG for the cohort was 98.2 10 
mg/dL.
46
 Less than 1% of the HEALTHY participants had a FPG in the diabetic range at the 11 
onset of the study.
46
   12 
 13 
Pathophysiology of Youth T2D 14 
Glucose homeostasis is maintained by a delicate coupling of insulin secretion, from the 15 
pancreatic β-cells, with insulin sensitivity (skeletal muscle, adipose tissue and hepatic)
47
 (Figure 16 
1). This relationship which is an expression of β-cell function relative to insulin sensitivity is 17 
best described by a hyperbolic function called the disposition index (DI). It is the product of 18 
insulin sensitivity and β-cell function which is a constant for a given glucose tolerance in any 19 
one individual. When insulin sensitivity declines, insulin secretion must increase to maintain 20 
glucose tolerance (Figure 1). Overweight and obesity are major contributors to the development 21 
of insulin resistance. In the presence of robust pancreatic β-cell compensatory insulin secretion, 22 
glucose homeostasis remains normal. When β-cells are no longer able to secrete sufficient 23 
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insulin to overcome insulin resistance, IGT ensues progressing to T2D (Figure 1). Abnormalities 1 
in other hormones, such as hyperglucagonemia, decreased incretin effect and raised 2 
concentrations of other counter-regulatory hormones also contribute to insulin resistance, 3 
impaired insulin secretion and hyperglycemia (Figure 2).
48, 49
  4 
Much of the knowledge about the pathophysiology of T2D had come from studies in 5 
animals and adults. However, in the past two decades, cross-sectional and longitudinal studies in 6 
pediatrics significantly advanced our understanding of the pathophysiology of prediabetes and 7 
T2D in youth.   8 
Studies in youth T2D using a variety of methods demonstrate highly variable degrees of 9 
insulin resistance and β-cell deficiency, the two key components in T2D pathogenesis. Gungor et 10 
al., used the hyperinsulinemic-euglycemic clamp to assess in vivo insulin sensitivity and the 11 
hyperglycemic clamp to assess β-cell function in obese youth with recently diagnosed T2D in 12 
comparison with obese non-diabetic peers matched for BMI, body composition and abdominal 13 
adiposity.
6
 Adolescents with T2D had evidence of severe peripheral and hepatic insulin 14 
resistance with ~ 50% lower in vivo insulin sensitivity, elevated fasting hepatic glucose 15 
production together with significantly lower adiponectin concentrations. This severe insulin 16 
resistance was accompanied with severe β-cell failure, such that first phase insulin secretion was 17 
~ 75% lower and second phase insulin secretion ~ 55% lower in T2D adolescents. β-cell 18 
function relative to insulin sensitivity, i.e. the DI was ~ 85% lower in T2D youth compared with 19 
their non-diabetic, equally obese peers (Figure 3A). Weiss et al., using the hyperglycemic clamp 20 
and modeling of glucose-stimulated insulin secretion also showed that glucose sensitivity of first 21 
and second-phase insulin secretion were impaired in obese youth with T2D compared with obese 22 
non-diabetic peers.
50
 A Japanese study using an insulin-modified frequently sampled intravenous 23 
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glucose tolerance test (IVGTT) and the minimal model analysis, also demonstrated lower first 1 
phase insulin release in obese adolescents with T2D compared with the non-diabetic group.
51
 In 2 
this study, insulin sensitivity was not different; however, body composition and fat topography 3 
were not evaluated. In another study using IVGTT, acute insulin release, insulin sensitivity and 4 
DI were lower in obese adolescents with T2D compared with non-diabetic controls.
52
 5 
Interestingly, β-cell failure in T2D adolescents was not reflected in an elevated proinsulin to 6 
insulin ratio.
52
 A study from France, evaluated adolescents with T2D without a comparison 7 
group and concluded that all patients showed decreased peripheral glucose uptake to the same 8 
extent, but highly variable insulin responses under graded glucose infusion and arginine 9 
stimulation (a sixty-four fold difference in DI between the lowest and the highest).
53 
Using the 10 
same approach of graded glucose infusion and after intravenous arginine at > 22 mM of blood 11 
glucose concentration, insulin responses and acute insulin release were blunted, 85% and 55% 12 
respectively, in adolescents with T2D compared with non-diabetic controls.
54
  13 
In the TODAY cohort, using fasting and OGTT-derived surrogate indices of insulin 14 
sensitivity and secretion, it was observed that with increasing HbA1c quartiles β-cell function 15 
declined both at screening and randomization, implying that glycemic control was associated 16 
with residual β-cell function and not insulin sensitivity.
55
 Lastly, a recent study from our group 17 
using mathematical modeling of β-cell function during an oral glucose tolerance test established 18 
that β-cell function parameters were 40-65% lower in obese youth with T2D compared with 19 
NGT
7
, consistent with our prior clamp data.
6  
Additionally however, and for the first time, 20 
evaluation of incretin effect demonstrated that youth with T2D exhibit ~ 38% reduced incretin 21 
effect compared with NGT without reduction in incretin hormones (Figure 3B).
7
           22 
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With regard to hyperglucagonemia and its pathophysiological role,
48,49
 the limited data in 1 
pediatric T2D are controversial.
7, 52, 56, 57
 In one study, fasting plasma glucagon and the degree of 2 
suppression after glucose ingestion did not differ among adolescents with T2D, obese controls 3 
and lean controls.
52 
In contrast, a study using mixed-meal tolerance tests showed relative 4 
hyperglucagonemia in adolescents with T2D compared with BMI and puberty-matched normal 5 
controls and no suppression in glucagon concentrations despite their hyperglycemia.
56
 In a recent 6 
study of ours with a large number of obese youth with NGT, IGT and T2D, glucagon 7 
concentrations after an OGTT were highest in T2D followed by IGT and lowest in NGT 8 
indicative of relative hyperglucagonemia in the face of higher plasma glucose concentrations in 9 
T2D and IGT adolescents.
7
 In yet another study, glucagon concentrations before and after a 10 
hyperinsulinemic-euglycemic clamp were higher in obese IGT and obese-insulin resistant 11 
subjects compared with nonobese NGT subjects.
57
 In the same study, a longitudinal follow up of 12 
a subsample revealed that those who converted from NGT to IGT increased their fasting 13 
glucagon concentrations in comparison with those who remained NGT. All these studies, point 14 
to an important pathophysiologic role of hyperglucagonemia in youth T2D consistent with adult 15 
findings.  16 
 17 
Pathophysiology of Prediabetes in Youth 18 
Pre-diabetes, defined as IFG, IGT, or both, is associated with high risk of progression to 19 
T2D in adults.
42
 Cross-sectional and longitudinal studies in youth along the spectrum of 20 
dysglycemia from obese-normoglycemic, to obese dysglycemic/prediabetic, to obese T2D, show 21 
that it is β-cell failure that results in prediabetes and T2D in high-risk youth (Figure 3A), as has 22 
been shown in adults.
58, 59
 Using both the hyperinsulinemic-euglycemic clamp,  to measure 23 
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insulin sensitivity, and the hyperglycemic clamp, to measure 1
st
- and 2
nd
 phase insulin secretion; 1 
or, the intravenous glucose tolerance test and oral glucose tolerance test (OGTT) methodologies, 2 
pediatric researchers have  demonstrated declining insulin secretion relative to insulin sensitivity 3 
as the principle pathophysiologic mechanism associated with the development of  dysglycemia 4 
and T2D in youth (Figure 3A).
7, 50, 60-67
 Additionally, there appears to be α-cell up-regulation 5 
with hyperglucagonemia in obese insulin resistant and IGT youth compared with lean youth.
57
 6 
Importantly however, and even prior to reaching the universally accepted glycemic cut-points for 7 
the diagnosis of prediabetes, youth demonstrate declining β-cell function relative to insulin 8 
sensitivity along the continuum of what is considered to be normal fasting and stimulated plasma 9 
glucose concentrations.  Tfayli et al. studied obese youth with normal glucose tolerance and 10 
found that there is a significant and gradual decline in β-cell function  relative to insulin 11 
sensitivity (DI, measured with clamp methodology) as fasting plasma glucose concentrations  12 
increased from < 90 mg/dl to >100 to toward the threshold for diabetes (<126 mg/dL).
62
 At 13 
fasting glucose concentrations between > 90 to < 100 mg/dl, (the glycemic cut-point for impaired 14 
fasting plasma glucose 100 mg/dL), DI was ~49% lower than when fasting glucose was below 15 
90 mg/dl. Similarly, Burns et al., using clamp-derived DI and OGTT-derived DI elicited that 16 
youth with 2-hr OGTT glucose concentrations between 120 to <140 mg/dL (technically 17 
considered normal glucose tolerance values) had DI values that were 40% lower than youth with 18 
2-hr OGTT glucose concentrations below 120 mg/dL.
63
 Youth with OGTT 2-hr glucose 19 
concentrations > 200 had DI values up to 75% lower than youth with glucose concentrations 20 
below 120 mg/dL.
63
 Thus, even prior to developing glucose intolerance or prediabetes, there is 21 
evidence of β-cell dysfunction in obese youth.  In a longitudinal study, Giannini et al. showed   22 
that across rising categories of normal 2-hr glucose concentrations, obese NGT adolescents had 23 
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significant impairment of β-cell function relative to insulin sensitivity associated with the 1 
development of IGT.
64
 Age and DI were the best predictors of 2-hr glucose after two years of 2 
follow up.
64
 Similar observations regarding β-cell function were made when youth were 3 
categorized according to their HbA1c levels. Overweight/obese adolescents with HbA1c in the 4 
at-risk/pre-diabetes category (5.7 to <6.5%), had impaired β-cell function relative to insulin 5 
sensitivity compared with the normal HbA1c (<5.7%) category.
68
  Lastly, our cross sectional 6 
studies in obese youth reveal that not only there is impairment in β-cell function in prediabetes, 7 
but also there is significantly impaired incretin effect (Figure 3B).
7
 To summarize, even though 8 
insulin resistance is the earliest abnormality in obese adolescents
69
 there is evidence of impaired 9 
β-cell function in obesity, even in the so called normal glucose tolerance categories. This 10 
impairment gets progressively worse with worsening glycemia ultimately resulting in glucose 11 
intolerance and T2D. It is likely that a combination of obesity, genetics, the hormonal milieu, 12 
incretins and/or their effect, and metabolic alterations, such as glucotoxicity and/or lipotoxicity 13 
promote progressively deteriorating β-cell function against the backdrop of insulin resistance 14 
eventually culminating in prediabetes and T2D in at risk youth.  
 
15 
 16 
 17 
Natural History of Insulin Sensitivity and β-cell Function in Youth T2D and Effects of 18 
Treatment 19 
In 2004, in a preliminary case report we examined the progression in insulin sensitivity 20 
and secretion over a 6-year period in an adolescent with T2D.
70
 Her in vivo insulin sensitivity 21 
remained relatively stable but 80% lower than her peers. However, her first phase insulin 22 
secretion and β-cell function relative to insulin sensitivity declined precipitously over time to 23 
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~10% of her initial value. This translated to ~15%- per-year decline in β-cell function.  This was 1 
the first indication that the deterioration in β-cell function in youth T2D might be more 2 
accelerated than in adults.
71, 72
 Results of our follow up study, using the clamp method, 3 
concurred with the prior findings by demonstrating that there is rapid deterioration in β-cell 4 
function over time in youth T2D, but no significant change in peripheral or hepatic insulin 5 
sensitivity in the absence of weight or BMI change.
73
 After a median follow up of 20 months, β-6 
cell function declined ~ 20% per year. Such rapid deterioration in β-cell function could explain 7 
the clinical observation of worsening glycemic control and increasing insulin requirements by 8 
1.5-2 years after diagnosis of T2D in youth.
74
 Another observation in our study was the 9 
considerable inter-individual variability in the deterioration of β-cell function ranging from ~5-10 
50%.
73
 This is in agreement with the wide between-subject variability in C-peptide 11 
concentrations over the course of clinical follow up.
74
 This C-peptide variability was partly 12 
related to whether or not patients presented with ketoacidosis, in which case they had overall low 13 
C-peptide concentrations at presentation and follow up.  Thus, the variability in β-cell function at 14 
diagnosis and follow up may be related to different degrees of disease severity, how early or late 15 
a diagnosis is made, and how much β-cell reserve is left.   16 
The results of the TODAY study are in harmony with the above observations. Surrogate 17 
estimates of insulin sensitivity and β-cell function in the large TODAY cohort of 699 youth with 18 
T2D revealed rapid deterioration in β-cell function, around 20-35% per year.
75
  Furthermore, 19 
there was a significant difference in β-cell deterioration between those who failed to maintain 20 
glycemic control vs. those who did not fail but no difference in insulin sensitivity (Figure 4). 21 
Additionally, initial β-cell reserve and HbA1C at randomization were significant independent 22 
predictors of glycemic failure. Such observations suggest that efforts to reduce HbA1C and 23 
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preserve β-cell function before significant loss occurs may prove beneficial in the treatment of 1 
youth T2D. The effects of the TODAY treatments,  metformin alone, metformin plus 2 
rosiglitazone, and metformin plus lifestyle, on insulin sensitivity and β-cell function were  also 3 
examined.
75
 The results were as follows: 1) during the initial six months of therapy in youth with 4 
T2D, metformin plus rosiglitazone significantly improved insulin sensitivity and the oral 5 
disposition index (oDI) vs. the other two groups, 2) after the first 6 months and up to 4 years the 6 
changes in glucose homeostasis parameters (insulin sensitivity, insulinogenic index and oDI) 7 
were not different among the 3 treatment groups, 3) insulinogenic index and oDI were ~ 40-50% 8 
lower at baseline in those who failed to maintain glycemic control vs. those who did not fail, and 9 
4) while insulin sensitivity over time was not different between those who failed vs. those who 10 
did not fail, insulinogenic index and oDI deteriorated rapidly and progressively  in the former 11 
group (Figure 4).     12 
The SEARCH study also examined prospectively β-cell function, assessed by fasting C-13 
peptide in antibody negative youth (diagnosed before or after age 10) with and without evidence 14 
of genetic susceptibility to autoimmunity based on HLA DR/DQ genotypes.
76
 In youth 15 
diagnosed after the age of 10, the rate of decline in β-cell function was steeper in those with 16 
susceptible HLA DR/DQ genotypes, suggesting the possibility of undetected autoimmunity in 17 
these participants: ~30% per year in non-Hispanic white youth; ~20% per year in minority youth.  18 
Youth without susceptible HLA DR/DQ genotypes had lower rates of β-cell decline: ~15% per 19 
year in non-Hispanic white youth; ~5% per year in minority youth. On average, the estimated 20 
rate of decline among SEARCH youth with non-autoimmune, insulin-resistant diabetes was ~8% 21 
per year in the first 30 months following diagnosis; lower than the rate observed in TODAY.  22 
The reasons for these differences in rates of β-cell deterioration among the aforementioned 23 
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studies could be methodological differences, clamps in our studies vs. OGTT-derived estimates 1 
of insulin secretion adjusted for insulin sensitivity in TODAY vs. fasting C-peptide in SEARCH.  2 
Population differences and referral biases could also contribute given a well-controlled and 3 
protocol-driven clinical trial of diabetes treatment in TODAY vs. a population- based 4 
epidemiologic study in SEARCH.       5 
 6 
 7 
Risk Factors for T2D in Youth 8 
Non-modifiable Risk Factors 9 
There are modifiable and unmodifiable risk factors for T2D. Unmodifiable risk factors 10 
include genetics/epigenetics, manifested in the presence of a strong family history of T2D in 11 
first- or second-degree relative, or mother with gestational diabetes, minority race/ethnicity, and 12 
puberty.   13 
The presence of dysglycemia in a first-degree relative is associated with dysglycemia in 14 
offspring, even in the absence of obesity.
77-79
 Adults who have one parent with T2D have 15 
approximately 30-40% lifetime risk of developing diabetes and those who have both parents with 16 
T2D have 70% risk.
80
 Moreover, risk of developing T2D is 2-4 fold increased in an individual 17 
who has a sibling with T2D compared to the normal population. This is likely due to common 18 
genetic variations which have been linked with β-cell dysfunction and decreasing DI, conferring 19 
risk for prediabetes and T2D.
81
 Our studies demonstrate that the genetic heritability of T2D 20 
manifests metabolically in the first decade of life by impaired insulin sensitivity and reduced β-21 
cell function relative to insulin sensitivity in healthy youth with family history of T2D compared 22 
with those without a family history of diabetes.
82
 This metabolically evident genetic 23 
Page 16 of 72
http://www.nyas.org/forthcoming
Annals of the New York Academy of Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
unedited manuscript
17 
 
susceptibility when combined with environmental factors conducive to obesity and a sedentary 1 
lifestyle may ultimately translate to T2D. Indeed, in a study of obese youth, a genetic risk score 2 
for β-cell dysfunction from five SNPs known to modulate insulin secretion was associated with 3 
progressive worsening of the dynamic phase of insulin secretion and a higher chance of 4 
progression from NGT to IGT/T2D.
83
 Genome wide association studies (GWAS) in adults have 5 
identified more than 64 genetic variants associated with T2D and 53 genetic variants associated 6 
with glycemic traits of fasting glucose, fasting insulin, and 2-hour OGTT glucose concentration, 7 
most pointing to genetic risk for β-cell dysfunction.
84
 However, it is estimated that the currently 8 
identified genetic variants account only for approximately 10% of the heritability of T2D.
 85, 86
 9 
Thus, common genetic variants are not yet useful for clinical prediction, and much work remains 10 
to discover the “missing heritability”.  Progress to date on the genetics of T2D in youth is 11 
limited.  In the Oji-Cree Native Canadians, the genetic variant, G319S, a variant of HNF1A 12 
strongly predisposes to diabetes in children and adults.
87
  Common variants in the transcription 13 
factor 7-like 2 (TCF7L2) gene have been associated with T2D, increasing the odds for T2D 14 
nearly 2-fold in African American youth.
88 
 Both SEARCH and TODAY are participating in a 15 
T2D Genetic Consortium that should provide novel information regarding the genetic 16 
background of T2D in youth.   17 
Evidence from both animal and human studies suggests that maternal obesity and 18 
gestational diabetes mellitus (GDM) is contributing to the increase in obesity and T2D in 19 
youth.
89, 90
 Since up to 10% of pregnancies are affected by GDM, and this percentage has been 20 
increasing, it poses increasing unmodifiable risk for affected youth.
91
 In the TODAY cohort of 21 
adolescents with T2D one third was born after a pregnancy complicated by pre-existing diabetes 22 
or GDM.
13
 In the SEARCH for Diabetes in Youth study, exposure to maternal diabetes and 23 
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exposure to maternal obesity were independently associated with T2D in adolescents and overall, 1 
47.2% of T2D in the cohort (n=79) could be attributed to intrauterine exposure to maternal 2 
diabetes and obesity.
92 
  3 
As stated above under the epidemiology section, incidence and prevalence of T2D is 4 
highest among minority youth (Table 1).
12
 This is most likely of multifactorial nature, including 5 
genetics, cultural/environmental influences, and metabolic characteristics. A detailed discussion 6 
is beyond the scope of this review except to state that several groups have demonstrated 7 
significant racial differences in insulin sensitivity and secretion that might heighten the risk of 8 
T2D compared with their white peers.
93-98
 9 
T2D typically occurs in adolescents at mid puberty (mean age 14 years in the TODAY 10 
study).
13
 Puberty is a vulnerable period for the development of dysglycemia, due to puberty-11 
related transient insulin resistance. Cross sectional and longitudinal studies show that insulin 12 
sensitivity declines by around 25-30% as youth transition from pre-puberty to puberty.
99, 100
 In 13 
the presence of normally functioning β-cells, puberty-related insulin resistance is compensated 14 
by increased insulin secretion/hyperinsulinemia. In youth who are genetically predisposed to 15 
develop prediabetes and/or T2D, β-cell compensation is inadequate due to impaired β-cell 16 
function with a progressive decline in the DI ultimately resulting in dysglycemia.
97, 101
    17 
 18 
 19 
Modifiable Risk Factors 20 
The major modifiable risk factor for T2D is obesity and lifestyle habits of excess 21 
nutritional intake and decreased energy expenditure and consequent insulin resistance. 22 
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Widespread obesity, especially in minority race/ethnicity populations in the U.S., is a result of 1 
nutritional factors associated with a surplus of “Western diet” and overall decline in physical 2 
activity and increased sedentary behaviors.  Other potentially modifiable risk factors for T2D in 3 
adolescents and young adults which may be associated with obesity include chronic stress and/or 4 
depressed mood
102-108 
and sleep-related disorders.
109-117
 Our studies in obese adolescents show 5 
that obstructive sleep apnea and poor sleep quality are associated with visceral adiposity, reduced 6 
insulin sensitivity, cardiometabolic and T2D risk markers.
111, 117, 118
 Treatment and or prevention 7 
of obstructive sleep apnea or interventions to improve sleep quality may decrease risk for T2D, 8 
but this is yet to be determined. We also found that depressive symptoms, particularly negative 9 
mood, anhedonia, and negative self-esteem are associated with risk markers for T2D including 10 
higher fasting and OGTT-stimulated glucose concentrations, and lower insulin secretion relative 11 
to insulin sensitivity.
103
 Moreover, a prospective pediatric study found depressive symptoms to 12 
be a significant predictor of fasting markers of insulin resistance after a mean follow-up of 6-13 
years, even after controlling for change in BMI and other confounding variables.
107
 It is yet to be 14 
determined though whether interventions to improve depressive symptoms could reduce risk for 15 
T2D.   16 
 17 
 18 
Diagnosis of T2D in Youth 19 
The laboratory glycemia-based diagnostic criteria for DM and prediabetes are the same 20 
for youth and adults, regardless of type of diabetes, as shown in Table 2.
119
 Screening for T2D in 21 
high-risk youth is generally recommended, as prediabetes and early T2D are asymptomatic.
120, 
22 
121
 Expert Committees and the American Diabetes Association have endorsed the use of fasting 23 
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plasma glucose or HbA1C for screening of overweight or obese (BMI ≥85
th
 percentile) youth 1 
who have at least two additional T2D risk factors, starting at the age of ten years or at the onset 2 
of puberty, if this occurs first.
42, 120
 The rationale for beginning screening at the age of 10, or 3 
sooner if puberty begins earlier, stems from the association of pubertal insulin resistance with 4 
increased blood glucose concentrations during adolescence. The recommended frequency of 5 
screening is every other year, or sooner if risk factors increase or diabetes symptoms are present.    6 
The diagnostic criteria for DM were developed based on lower-end glycemic thresholds 7 
predicting the presence of retinopathy in adult populations.
122-127
 Because the risk for progression 8 
from a prediabetic state to DM is a continuum, a defined glycemic cut-off cannot adequately 9 
reflect the earliest stages of the disease in development, but must reliably predict undesired 10 
outcomes, such as retinopathy, that could be improved with treatment. There is an absence of 11 
pediatric data on the relationships between these universally applied glycemic thresholds and the 12 
development of long-term complications in youth. Thus, the applicability of these cut-points 13 
(particularly HbA1C) in pediatric and adolescent patient populations has been questioned.
128-130
  14 
The transient rise in blood glucose concentrations during puberty, as seen in the HEALTHY 15 
study cohort (mean fasting plasma glucose of 98.2 mg/dL), may not indicate pathology if it 16 
reverses spontaneously and β-cell function isn’t compromised.  Indeed, studies have shown that 17 
abnormal β-cell function is evident in advance of meeting accepted criteria for the diagnosis of 18 
prediabetes or diabetes as elaborated above.
63, 68
 As youth with T2D mature over the next few 19 
decades, it will be particularly important to further explore glycemic predictors of development 20 
of diabetes-related complications. This will allow pediatric-specific diagnostic cut-points, if this 21 
is deemed necessary.   22 
 23 
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Islet Autoantibody Positivity in Youth with Phenotypic T2D 1 
In making a clinical diagnosis of T2D, the major diagnostic criterion is 2 
overweight/obesity. However, with the increasing rates of obesity in children with autoimmune 3 
T1D, the clinical distinction between youth with T2D and obese youth with autoimmune T1D is 4 
difficult and imperfect without measuring pancreatic autoantibodies.
5, 40, 131-133
 Between two 5 
periods, 1979-1989 and 1990-1998, the prevalence of overweight at diagnosis of T1D in children 6 
tripled.
14
 The SEARCH for diabetes in youth study revealed that among youth with T1D, 22.1% 7 
were overweight compared with 16.1% without diabetes and 12.6% were obese.
15
 In the 8 
Pediatric Diabetes Consortium, among 857 participants, 10% were overweight and 9% obese at 9 
diagnosis.
16
 This phenomenon is not unique to the U.S. because it has been reported from other 10 
parts of the world too.
134-136
 The distinction between youth with T2D and obese youth with 11 
autoimmune T1D is further blurred because not infrequently youth with T2D present in DKA.
137, 
12 
138
 Moreover, and as stated under the Introduction and Epidemiology sections, a number of youth 13 
clinically diagnosed with T2D have evidence of islet-autoimmunity, with autoantibodies present 14 
in 10-75% of patients.
35-41, 132
 Several theories and terminologies have been proposed, such as 15 
hybrid diabetes, double diabetes, diabetes type 1.5, and latent autoimmune diabetes of youth, to 16 
refer to this subset of young patients with a clinical phenotype consistent with T2D and evidence 17 
of autoimmunity consistent with T1D.
37, 39, 139, 140
   18 
SEARCH described four categories of diabetes using autoimmunity (at least 1 of two 19 
autoantibodies, GAD and IA2) and insulin sensitivity (estimated using an equation which 20 
includes waist circumference, HbA1C, and triglycerides).
132
 Most subjects fell into either the 21 
autoimmune insulin sensitive (54.5%) or nonautoimmune insulin resistant categories (15.9%) 22 
and had characteristics associated with the traditional description of type 1 or 2 diabetes. The 23 
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group classified as autoimmune insulin resistant (19.5%) had similar prevalence of 1 
autoantibodies and similar distribution of HLA risk genotypes to those in the autoimmune insulin 2 
sensitive group, suggesting that it includes individuals with type 1 diabetes who are obese. The 3 
group categorized as nonautoimmune insulin sensitive (10.1%) likely included subjects with 4 
undetected autoimmunity and possibly those with monogenic diabetes. Considering that insulin 5 
sensitivity in normal humans is a wide spectrum, driven by genetics and strongly modulated by 6 
obesity, it is not surprising to see the same hold true for individuals with diabetes with or without 7 
autoimmunity especially when the formula used to estimate insulin sensitivity is based on waist 8 
circumference, a major determinant of insulin sensitivity.
141, 142
  9 
We used a variety of experimental methods, including the hyperinsulinemic-euglycemic 10 
clamp together with the hyperglycemic clamp, the OGTT and the mixed meal to probe assess 11 
pathophysiological differences in insulin sensitivity and β-cell function between islet 12 
autoantibody-negative (Ab
-
) and –positive (Ab
+
)  (GAD65 and IA2) in youth with clinically 13 
diagnosed T2D in comparison with non-diabetic matched-peers.
8, 9, 143
 As depicted in Figure 5A, 14 
insulin-stimulated glucose disposal was significantly lower in Ab
-
 compared with Ab
+
 and 15 
compared with obese non-diabetic adolescents, with no difference between the latter two 16 
groups.
9
 This is suggestive of an inherent (genetic/epigenetic) insulin resistance in Ab
-
 youth 17 
which is not the case in Ab
+
 youth whose insulin resistance appears to be consequent to their 18 
obesity.  On the other hand, Ab
+
 youth had severe first and second phase insulin deficiency, 19 
while Ab
-
 youth had relative deficiency
9
 (Figure 5B). There also appeared to be an autoantibody 20 
dose effect phenomenon on first and second phase insulin secretion both of which were 21 
significantly lower in double-antibody vs. single-antibody positive patients.
9
 β-cell function 22 
relative to insulin sensitivity, DI, was similar between Ab
-
 and Ab
+
 groups (Figure 5C), but 23 
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obviously mediated through different mechanisms; through severe insulin resistance in the 1 
former and through severe insulin deficiency in the latter.
9
  Moreover, youth who were Ab
-
 2 
exhibited features of the metabolic syndrome (elevated systolic blood pressure and ALT) 3 
typically seen with insulin resistance while youth who were Ab
+
 had significantly more frequent 4 
ketonuria at initial presentation.
9
 State-of-the-art clamp studies were required to detect these 5 
metabolic/pathophysiological differences, as OGTT-derived surrogate indices of insulin 6 
sensitivity and insulin secretion were not different between Ab
-
 and Ab
+
 patients, except for 7 
lower fasting and stimulated C-peptide in the latter group.
8
  During a liquid mixed-meal test, C-8 
peptide indices of β-cell function were lower and insulin sensitivity higher in Ab
+
 vs. Ab
-
 9 
phenotypic T2D patients.
143
 Though fasting and stimulated C-peptide, which were significantly 10 
different between the two groups, had high sensitivity and specificity as markers of Ab
+ 
status, 11 
there was appreciable overlap between Ab
-
 (fasting C-peptide mean: 4.1 and range 1.3-10.1 12 
ng/ml) and Ab
+ 
(fasting C-peptide mean 2.4 and range 1.4-3.5 ng/ml) patients. In agreement with 13 
our findings, the TODAY study showed that the 10% of clinically diagnosed youth with T2D 14 
who had positive autoantibodies, had lower fasting C-peptide concentrations, fewer 15 
cardiometabolic risk factors (lower blood pressure and triglycerides), higher HbA1C, lower BMI, 16 
and less acanthosis nigricans at screening.
35
 In addition Ab
+ 
T2D patients were mostly non-17 
Hispanic whites, with less female predilection and less frequent family history of DM. An 18 
evaluation of our clinic population of obese Ab
+
 vs Ab
-
 T2D patients at diagnosis and their 19 
clinical course over time revealed similar findings; Ab
+
 youth were younger, had higher rates of 20 
ketosis, higher HbA1C and glucose concentrations, and lower insulin and C-peptide 21 
concentration compared with Ab
-
 patients.
40
 The latter patients had higher BMI z scores and 22 
cardiometabolic risk factors at diagnosis and such differences persisted over time. Longitudinal 23 
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data analysis uncovered that deterioration in BMI z-score significantly affected systolic blood 1 
pressure and ALT, but the lipid profile was mostly impacted by HbA1C and glycemic control 2 
regardless of antibody status.
40
 3 
These important pathophysiologic differences in insulin sensitivity and secretion in Ab
+
 4 
vs. Ab
-
 youth with obesity and diabetes, and the contrast in their presentation and clinical course 5 
imply that the former is autoimmune T1D against the backdrop of obesity and the latter is 6 
“garden variety” T2D. Both forms of diabetes are heterogeneous but the distinction between the 7 
two may have important implications for treatment.
144
 In Ab
+ 
youth, the progression to insulin 8 
dependency is significantly faster and glycemic control is inferior compared with Ab
-
youth.
35, 37
  9 
While laboratory assessment for islet autoantibodies could be of value in distinguishing the two 10 
types of diabetes, currently available commercial assays are not always sufficiently sensitive to 11 
detect low antibody titers yielding negative results when in fact the patient may have 12 
autoimmune diabetes.   13 
 14 
Treatment of T2D in Youth 15 
The implications of developing T2D at a young age are worrisome, due to the risk of 16 
microvascular and macrovascular complications ensuing early in life. Therefore, it is imperative 17 
that T2D be treated aggressively to glycemic goals similar to those for youth with T1D as the 18 
risks due to hyperglycemia are present regardless of the type of diabetes. The treatment of youth 19 
T2D necessitates a multi-faceted approach to alleviate both the insulin resistance and β-cell 20 
failure, achieve glycemic control, and prevent acute and chronic complications. This could only 21 
be achieved through a diabetes team which includes the patient, family, physician, behavioral 22 
specialist, nurse educator, dietician, and school personnel. This approach should focus on family-23 
Page 24 of 72
http://www.nyas.org/forthcoming
Annals of the New York Academy of Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
unedited manuscript
25 
 
based behavioral lifestyle intervention together with pharmacotherapy with the objectives of 1 
weight loss or prevention of continued weight gain, adoption of healthier lifestyle habits, 2 
normalization of glycemia, and control of comorbidities such as hypertension, dyslipidemia, 3 
nephropathy and hepatic steatosis.
145  
Efforts should be geared to individualize therapy in T2D 4 
not only based on the heterogeneity of the disorder but also based on ethnic/cultural beliefs and 5 
traditions.
144
 Until recently, and before the TODAY study results were unraveled, there were few 6 
data to guide treatment. Most pediatric recommendations were based on studies in adults with 7 
T2D. However, in stark contrast to adult T2D a major barrier in treating youth T2D is the lack of 8 
approved oral pharamco-theraputic options besides metformin which is the only approved oral 9 
antidiabetic agent in youth T2D.
146
  10 
In adults, lifestyle change leading to better nutrition, weight control, and increased physical 11 
activity effectively prevents or delays the onset of T2D.
147
 In youth, cardiorespiratory fitness is 12 
directly associated with insulin sensitivity, and supervised exercise intervention in obese non-13 
diabetic youth improves insulin sensitivity, even in the absence of weight loss.
148-150 
The effects 14 
of similar interventions in youth T2D with or without weight loss remain to be shown. Weight 15 
reduction and individualized nutrition therapy is important since, by definition, all youth in 16 
North America with T2D are overweight/obese. Ideally, care should include guidance by a 17 
nutritionist with elimination of sugar containing beverages and high-fat, high calorie foods, and 18 
establishment of a regular meal schedule, portion control, and improvement in food choices and 19 
encouragement of high fiber intake.
151
 Despite the overall belief that lifestyle intervention could 20 
be beneficial in glycemic control in youth with T2D, the TODAY study, described in detail 21 
above, revealed that the addition of intensive lifestyle intervention to metformin was not superior 22 
to metformin alone in maintaining glycemic durability nor in achieving better weight loss.
17
 At 6 23 
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months the proportion of participants with meaningful weight loss (defined as a reduction of at 1 
least 7 percentage points in percent overweight) in the metformin plus lifestyle intervention 2 
group (31.2%) was not significantly different from the metformin alone group (24.3%).
17
 3 
Furthermore, the average change in percent overweight at 24 months was similar between the 4 
metformin plus lifestyle intervention group (-5.02 percentage points) and the metformin alone 5 
group (-4.42 percentage points).
17
 Additional evaluation revealed that even though there were 6 
significant but small differences in the change in adiposity parameters (BMI, percent body fat 7 
and absolute fat mass) between metformin vs. metformin plus lifestyle at 6 months, there were 8 
none at 24 months.
152
 The reasons why intensive lifestyle intervention did not prove more 9 
effective in TODAY remain to be investigated.   10 
  Recommendations for treating youth T2D include initiating therapy with metformin, in 11 
escalating doses up to a maximum therapeutic dose of 1000 mg twice a day, combined with 12 
lifestyle intervention, aiming for a target HbA1C < 7% by some organizations and < 6.5% by 13 
others.
5, 145, 153
 If and when the HbA1C target is not achieved, basal insulin treatment is added to 14 
the regimen. In TODAY, the overall treatment failure rate (defined by either an HbA1C >8% for 15 
6 months or inability to wean from temporary insulin therapy within 3 months of acute metabolic 16 
decompensation) was high. After a median of 11.5 months (mean follow-up 3.86 years) 45.6% of 17 
participants had glycemic failure.
17
 Treatment failure rates were greatest in the metformin alone 18 
group (51.7%), and lowest in the metformin plus rosiglitazone group (38.6%, p=0.006).  19 
Metformin plus lifestyle group demonstrated an intermediate failure rate (46.6%) which was not 20 
statistically different from either of the other two interventions (Figure 6). While BMI increased 21 
during the trial for the entire study group, the metformin plus rosiglitazone group had a clearly 22 
significant BMI increase. Subgroup analysis revealed significant racial/ethnic disparities. Overall 23 
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failure rates, regardless of treatment assignment, were greatest in non-Hispanic blacks (52.8%), 1 
Hispanics (45.0%), and lowest in non-Hispanic whites (36.6%).
17
 Non-Hispanic blacks fared 2 
poorly when assigned to metformin alone (66.2% failure rate) versus non-Hispanic whites 3 
(44.9%) or Hispanics (44.0%). Racial/ethnic contrast in these failure rates were not related to 4 
difference in insulin sensitivity or secretion parameters at randomization.
55, 75
 Additionally, there 5 
were gender related differences in response to treatment. Metformin plus rosiglitazone was more 6 
effective in girls than in boys (p=0.03), and boys met the metabolic endpoint more often than 7 
girls (48.2% vs. 44.3%, p=0.02) regardless of therapeutic assignment.
17
 These race-related 8 
observations in TODAY are in agreement with diabetes clinic reports demonstrating higher 9 
HbA1C in black vs. white youth with T2D.
154
   10 
When compared with adults, the failure rate on metformin monotherapy in youth despite 11 
better than 80% adherence during the first year was startlingly high.
72, 155, 156
 Treatment failure 12 
rates of monotherapy with metformin in adults have been reported as 21%
156
- 42%
155
 over 13 
similar time periods. The findings from the subgroup analysis and comparison with adult trials 14 
indicate a need for different strategies to prevent and treat T2D in youth, which may vary 15 
according to race / ethnicity. It will be critical to evaluate safety and efficacy of additional agents 16 
targeted to T2D, including incretin-mimetics, in adolescents and young adults to ensure adequate 17 
treatment of this disease with devastating complications. Given the knowledge that β-cell failure 18 
is a primary feature of the pathophysiology, there is broad interest in investigating therapies 19 
directed toward the preservation or restoration of β-cell function.   20 
At the moment the only approved oral antidiabetic medication for youth T2D is metformin. 21 
The progress in successfully completing regulatory trials for various pharmacotherapies has been 22 
painfully slow  due to the still low numbers of youth with T2D, the stringent inclusion/exclusion 23 
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criteria imposed by the regulatory agencies and the frequent use of insulin even at the time of 1 
diagnosis.  The dire need for quick action to address the lack of therapeutic options which target 2 
the various pathophysiological mechanisms for T2D in youth has led to the formation of 3 
collaborative efforts. Involved parties are the U.S. Food and Drug Administration, European 4 
Network of Pediatric Research at the European Medicines Agency, Eunice Kennedy Shriver 5 
National Institute of Child Health and Human Development’s Diabetes Working Group, and 6 
pharmaceutical companies to collect efficacy and safety clinical trial data to inform treatment 7 
algorithms.
157
 8 
     9 
T2D Complications in Youth  10 
Microvascular Complications 11 
In adults, diabetes-related microvascular complications - retinopathy, nephropathy and 12 
neuropathy result in major disabilities.
158-162
 It is well-known that diabetes duration and glycemic 13 
control are closely associated with the development of these complications. Evidence of 14 
microvascular complications and risk markers for macrovascular complications in youth with 15 
T2D are present early in the course of the disease within the first 5 years and progress rapidly 16 
(Table 3).
163-169
  Both  SEARCH  and TODAY have contributed to advancing our knowledge  17 
regarding complications in youth with T2D and their burden.
163-167,
 
169
 Vigilant attention to 18 
glycemic control, blood pressure management, dyslipidemia, insulin sensitization, and regular 19 
screening are recommended for early detection and for reducing diabetes-related complications 20 
in youth with T2D.
170
    21 
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In adults, retinopathy is a frequently identified complication associated with newly 1 
diagnosed T2D
171
, and is not uncommon in adolescents with T2D.  Studies in Pima Indians show 2 
that the risk of developing retinopathy is lower in those diagnosed before 20 years of age 3 
compared with those diagnosed later in life.
172
 The SEARCH study estimated a 42% prevalence 4 
of diabetic retinopathy in youth with T2D, with a mean diabetes duration of 7.2 years, vs. 17% in 5 
patients with T1D.
20  
In contrast, the TODAY study, using fundus photography, revealed a lower 6 
prevalence of 13.7% in youth with T2D with a mean time of diagnosis of 4.9 years.
164
 Most of 7 
these youth had early signs of retinopathy, with 90.1% classified as “very mild nonproliferative 8 
retinopathy” (microaneurysms or other vascular pathology such as intraretinal hemorrhage or 9 
cotton wool infarct), and 9.8% classified as “mild nonproliferative retinopathy” (microaneurysms 10 
plus other vascular pathology).
164
 The prevalence of retinopathy in TODAY increased with 11 
increasing HbA1C, increasing age at the time of fundus photography and increasing diabetes 12 
duration.
164
 Interestingly however, lower BMI appeared to be a risk factor for retinopathy in 13 
TODAY youth.
164
 This association remains unexplained, and there are conflicting reports in the 14 
adult literature about the relationship between obesity and retinopathy.
173, 174
 While in adults it is 15 
clear that the presence of even mild retinopathy is predictive of cardiovascular disease and stroke 16 
175-180
, youth T2D has not been around long enough to provide this crucial information which 17 
requires long-term observations. The TODAY extension study will address the long-term follow 18 
up and outcome of youth with T2D.      19 
Youth with T2D also have higher rates of microalbuminuria, which heralds nephropathy, 20 
than peers with T1D.
181
 In the Australian experience microalbuminuria (defined as > 20 µg/min) 21 
was present in 28% of youth with T2D vs. 6% with T1D.
181
  In SEARCH 22% of youth with 22 
T2D had abnormal albumin to creatinine ratio (>30 µg/mg), as opposed to only 9.2% of patients 23 
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with T1D.
18, 182
 The Japanese data show 44.4% incident nephropathy in youth T2D vs. 20.2% in 1 
T1D.
183
 In TODAY the prevalence of microalbuminuria was 6.3% at baseline and soared to 2 
16.6% by the end of the study (mean follow-up of 3.9 years, mean age 14.0 [SD 2.0]) (Table 3 
3).
166
 This increasing prevalence was regardless of treatment modality but closely related to 4 
glycemic control, HbA1c. In the Pima Indian experience, end stage renal disease and consequent 5 
mortality were higher in youth onset (< 20 yrs. of age) vs. older onset (20-<55 yrs.) T2D (25 vs. 6 
5.4 per 1000 patient-years for end-stage renal disease and 15.4 vs 7.3 for death rate, 7 
respectively).
184
 Canadian First Nation Children with T2D have a fourfold increased risk of renal 8 
failure versus youth with type 1 diabetes.
185
 Some studies have also  shown associations between 9 
reduced insulin sensitivity and microalbuminuria or established nephropathy, potentially  related 10 
to a proinflammatory state accompanied by insulin resistance leading to microvascular 11 
damage.
18,
 
186, 187
 Further, adult data exhibit that blood pressure variability plays a role in the 12 
development of nephropathy and atherosclerosis.
188-190
  Whether or not similar observations will 13 
hold true in youth T2D remains to be learned. Lastly, against this backdrop of increased risk of 14 
nephropathy in adolescents with T2D, the recommendation is to screen at diagnosis and annually 15 
thereafter for microalbuminuria by measuring the albumin-to-creatinine ratio in a random urine 16 
sample.
145, 151, 185
 Patients with elevated albumin-to-creatinine ratio should have repeat 17 
confirmation on at least two of three samples during the subsequent six months.
153
 If elevated 18 
urine albumin to creatinine ratio is confirmed, it is recommended to initiate an angiotensin 19 
converting enzyme (ACE) inhibitor and titrated every 3 months until the ratio is normal. 20 
Additionally, vigilant control of glycemia and other comorbidities must be implemented.
145, 151, 
21 
153
 22 
Precursors of Macrovascular Complications 23 
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 Adults with T2D have increased cardiovascular disease and event rates (myocardial 1 
infarction, stroke), despite treatment of hypertension and lipid abnormalities.
191
 Unfortunately, 2 
hypertension and dyslipidemia are common in youth with T2D (Table 3) and predict 3 
cardiovascular disease events in adults.
163, 166, 169, 192 Patterns of dyslipidemia conducive to 4 
macrovascular disease are high and more prevalent in youth with T2D compared with T1D.
 169, 
5 
193
 In  SEARCH youth with T2D had:  elevated triglycerides (65%), decreased HDL cholesterol 6 
(60%), elevated apoB (36%) and dense LDL cholesterol (36%).
169
  Hypertension too is more 7 
prevalent in youth T2D compared with T1D: 26% vs. 16%, in  Canadian First Nation 8 
population
194
  and 73% in youth with T2D in SEARCH between 2006-2013.
169
  In the TODAY 9 
study, 11.6% of the participants were hypertensive at baseline and this escalated to 33.8% by the 10 
end of the study (mean follow-up 3.9 years) (Table 3).
166
 The greatest risk for hypertension was 11 
male sex and higher BMI, with no relationship to  treatment modality or glycemic control.
166
  12 
Dyslipidemia and chronic inflammation were common in TODAY youth too, and worsened over 13 
time (Table 3).
163
 Diabetes treatment per se was generally inadequate to control this worsening 14 
risk.
163 
These data are in concert with observations in adults showing that treating to glycemic 15 
goals of adults with T2D didn’t improve cardiovascular event risk  in the Action to Control 16 
Cardiovascular Risk in Diabetes (ACCORD) trial.
195
 Nevertheless, in patients with T1D there is 17 
evidence that intensive diabetes therapy with attention to glycemic control has long-term 18 
beneficial effects on the risk of cardiovascular disease.
191, 195
    19 
               Data from our laboratory regarding early subclinical biomarkers of atherosclerosis 20 
exhibited that adolescents with T2D have significantly higher pulse wave velocity, a measure of 21 
arterial stiffness, compared with obese and normal-weight healthy peers, suggestive of premature 22 
aging of their cardiovascular system.
196
 Additionally, the SEARCH study demonstrated that 23 
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youth with T2D have worse arterial stiffness than youth with T1D, and that increased central 1 
adiposity and blood pressure were associated with arterial stiffness, independent of diabetes 2 
type.
197
 In a follow up study of obese adolescents with normal and abnormal glucose tolerance 3 
including T2D, we examined coronary artery calcification in addition to pulse wave velocity and 4 
intima-media thickness.
198
 These different biomarkers of subclinical atherosclerosis appeared to 5 
be differentially modulated; adiposity being the major determinant of coronary artery calcium 6 
independent of glycemia, while hyperglycemia/HbA1C was for intima-media thickness, and 7 
insulin sensitivity for arterial stiffness.
198
 Considering that all T2D youth harbor obesity, insulin 8 
resistance and hyperglycemia, it is imperative to implement longitudinal follow up of these 9 
subclinical biomarkers of atherosclerosis in this high risk population. In the meantime, current 10 
recommendations for youth T2D include blood pressure surveillance and management, and 11 
treatment of dyslipidemia according to American Heart Association recommendations.
199
                12 
Bearing in mind the significant differences in prevalence of hypertension, 13 
microalbuminuria and dyslipidemia between youth T2D and T1D, it is not surprising that the 14 
overall outcome is much worse in T2D than T1D. A population-based cohort study from Canada 15 
demonstrated that youth with T2D had an increased risk of any omplication with a hazard ratio 16 
of 1.47.
200
 Kaplan-Meier statistics revealed an earlier diagnosis of renal and neurologic 17 
complications in the T2D cohort manifesting within 5 years of diagnosis. Neuropathy, 18 
nephropathy, dialysis, blindness and amputation free survival rates were significantly lower in 19 
T2D compared with T1D with no difference in retinopathy.
200
 Such data were corroborated with 20 
Australian observations showing that case fatality is increased in young-onset T2D compared 21 
with T1D of similar age and diabetes duration, driven by cardiovascular deaths with a death 22 
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hazard ratio of 2 (p=0.003).
201
  Further, death occurred after shorter diabetes duration and at a 1 
younger age in T2D vs. T1D.
201
   2 
 3 
ComparisionComparison and Contrast between Adult T2D and Youth T2D 4 
            While T2D in adults has been around for a long time, youth T2D is relatively in its 5 
toddler stage. Though our knowledge of youth T2D has increased tremendously over the last 1-2 6 
decades, a lot still remains to be learned. Even though there are no head-to-head comparisons, 7 
data extracted from the literature would suggest that youth T2D may be a more aggressive 8 
disease than adult T2D. Therapeutic failure rates appear to be higher in youth compared with 9 
adults when comparing TODAY results with ADOPT (A Diabetes Outcome Progression Trial), 10 
and with other adult studies.
17, 156, 202
  Keeping in mind that the definition for glycemic failure 11 
may differ in these studies, the failure rate on metformin in youth was 51.7% vs. 21% in 12 
ADOPT.
17, 156
 The failure rate on metformin plus rosiglitazone in youth was 38.6% while in 13 
adults from the US Department of Defense data base was 14.3%.
17, 202
  Further, the higher failure 14 
rates to metformin in black youth in TODAY is in contrast to the reported greater effectiveness 15 
of metformin in black adults with T2D.
17, 203
   The change in insulin sensitivity with metformin 16 
monotherapy in TODAY youth was remarkably lower (-4.93%) than that in ADOPT (~13%).
75, 
17 
204
 Moreover, the deterioration in β-cell function in youth with T2D in TODAY appears to be 3-18 
4 fold faster compared with adults. Our clamp-generated data and TODAY data show on average 19 
20-35% decline per year in β-cell function in youth with T2D,
73, 75
 while the decline in adults is 20 
on average 7-11%.
71, 156, 202
 In the United Kingdom Prospective Diabetes Study (UKPDS), the 21 
estimated rate of decline of β-cell function, using the Homeostasis Model Assessment (HOMA 22 
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%B) index, was about 7% per year.
71, 205
 The ADOPT study of drug naïve adults with T2D with 1 
up to 3-yr duration utilized the insulinogenic index, similar to TODAY, as a measure of β-cell 2 
function.
204
 The insulinogenic index declined at a rate of ~ 7-11% per year in the total cohort.  3 
Other prospective studies of adult T2D have shown either stable fasting C-peptide concentrations 4 
over a 20 year follow up or insulin use required in only 1/3 of the patients over a 12 year follow 5 
up.
206,
 
207
  Whether or not such stark contrast between youth and adult T2D is driven by genetic 6 
heterogeneity of the disease, or susceptibility to autoimmunity driving declining β-cell function, 7 
or physiologic/metabolic maladaptation to childhood growth and development remains to be 8 
investigated.  9 
 10 
Summary 11 
The trajectory of childhood obesity not only is giving rise to youth T2D but also is 12 
clouding the phenotype of T1D making the distinction between the two difficult along the 13 
diabetes spectrum. Over the last 1-2 decades there has been tremendous advancement in our 14 
understanding of youth T2D, its risk factors, its pathophysiology, its clinical course and its 15 
complications. The TODAY results paint a very gloomy picture of youth T2D, showing high 16 
therapeutic failure rates with rapid deterioration in β-cell function necessitating initiating insulin 17 
treatment early in the course of the disease. Further, the TODAY showed high rates of 18 
comorbidities and complications with progressive and rapid worsening. Last, but not least, the 19 
preliminary impression is that youth T2D is a more aggressive disease than adult T2D. Against 20 
this backdrop, youth with T2D and their health care providers are up against a giant barrier, the 21 
lack of approved therapeutic agents to be used when metformin, the only approved therapy, fails 22 
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in these youth.  There is an urgent need for effective and safe pharmacotherapy in youth with 1 
established T2D, to help achieve target HbA1C, to reverse one or more of the underlying 2 
pathophysiological aberrations, to enhance energy expenditure and weight control, to sustain 3 
metabolic control, and ultimately reduce diabetes-related micro and macro vascular 4 
complications and death at a young age. There is also a dire need for interventions in youth with 5 
prediabetes to preserve β-cell function and protect it from progressive failure. Lastly, there is a 6 
desperate societal need for the prevention of youth obesity and diabetes for those at risk, to halt 7 
the projected four-fold increase in the number of youth with T2D by 2050.
34
 The burden of 8 
prevention does not fall only on the health care profession, but starts with the family, the school, 9 
the neighborhood, the society, the food industry, health care policy makers, economists and the 10 
government. The National Institutes of Health and the American Diabetes Association have 11 
called for the development of diabetes prevention approaches for positive lifestyle changes in 12 
adolescents.
208, 209
  The successful smoking stopp ge campaign should be the prototype for a 13 
successful obesity and T2D prevention campaign starting in utero.   14 
 15 
 16 
  17 
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Figure Legends 1 
Figure 1: The hyperbolic relationship between insulin secretion and insulin sensitivity.  2 
Lean, insulin sensitive e individuals require lower levels of insulinemia/insulin secretion; 3 
obese, insulin resistant but normoglycemic individuals compensate with increased insulin 4 
secretion.  Impaired glucose tolerance develops when insulin secretion is insufficient to 5 
overcome insulin resistance, and the disposition index (DI) which is β-cell function relative 6 
to insulin sensitivity (insulin secretion × insulin sensitivity) declines.  T2D occurs when 7 
insulin secretion further deteriorates, resulting in prevalent hyperglycemia.     8 
 9 
Figure 2: Pathogenic features of hyperglycemia in T2D. Adapted with permission from 10 
Defronzo, R.A.
8 
and
 
Tahrani, A.A. et al.
9
 11 
 12 
Figure 3: (A) Disposition index (DI) which is β-cell function relative to insulin sensitivity in 13 
obese adolescents with NGT, IFG, IGT, IFG/IGT, and T2D. Letters are significant post hoc 14 
analysis (a: T2D vs. NGT; b: T2D vs. IFG; c: T2D vs. IGT; e: NGT vs. IFG/IGT; f: NGT 15 
vs. IGT). Adapted with permission from Bacha, F. et al.
61
 (B) Incretin effect in obese youth 16 
with NGT, IGT and T2D. Letters are significant post hoc analysis (a: NGT vs. IGT; b: NGT 17 
vs. T2D). Adapted with permission from Michaliszyn, S. et al.
7
  18 
 19 
Figure 4: OGTT-derived measures of (A) insulin sensitivity, (B) insulinogenic index and 20 
(C) oral disposition index (oDI) by treatment failure (red: failed, blue: did not fail) with the 21 
three treatment groups combined (metformin alone, metformin plus rosiglitazone, 22 
metformin plus lifestyle) in the TODAY study. The P value refers to the overall effect of 23 
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failed vs. not failed group assignment in longitudinal models. Copyright © 2013, American 1 
Diabetes Association, Arslanian, S. et al.
 75
 2 
Figure 5:  (A) Insulin-stimulated glucose disposal (Rd) during the hyperinsulinemic-3 
euglycemic clamp. (B) First- and second-phase insulin secretion during the hyperglycemic 4 
clamp. (C) Disposition index (DI), i.e. β-cell function relative to insulin sensitivity. 5 
Antibody negative (Ab
-
: red), antibody positive (Ab
+
: orange), obese non-diabetic controls 6 
(OBCN: blue), normal-weight controls (NWCN: green). Post hoc Bonferroni correction: 7 
Ab
− 
vs. Ab
+
, and Ab
− 
vs. OBCN subjects. Adapted with permission from Tfayli, H. et al.
9
 8 
Copyright © 2009, American Diabetes Association. 9 
 10 
Figure 6:  Overall TODAY study primary outcome results.  Survival curves by treatment 11 
group for the proportion of study participants free of glycemic failure (HbA1c <8.0%).
17
 12 
Copyright   2012 Massachusetts Medical Society. 13 
  14 
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Table 1.  Prevalence of Type 1 and Type 2 Diabetes in Youth by Demographic Characteristics in 
the U.S.
12
  
 Type 1 Diabetes Type 2 Diabetes 
Prevalence per 1000 by Age (years)    
     All ages; 0 - ≤ 19  1.93 0.46 
     0 - ≤ 4  0.29 - 
     5 - ≤ 9  1.35 - 
     10 - ≤ 14  2.69 0.23 
     15 - ≤ 19  3.22 0.68 
Prevalence per 1000 by Gender   
     Male 1.93 0.35 
     Female 1.93 0.58 
Prevalence per 1000 by Race/Ethnicity   
     American Indian 0.35 1.20 
     Asian Pacific Islander Black 0.60 0.34 
     Hispanic 1.29 0.79 
     Black 1.62 1.06 
     White 2.55 0.17 
Change in Prevalence (2001 – 2009) +0.45  +0.12 
Adjusted Prevalence Increase  23% 30% 
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Table 2.  American Diabetes Association Criteria for the Diagnosis of Diabetes Mellitus or Prediabetes   
DIABETES 
HbA1C ≥ 6.5%*   
OR 
 
Method should be NGSP certified, standardized to the 
DCCT assay. 
FPG ≥ 126 mg/dL (7.0 mmol/L)*   
OR 
Fasting is defined as no caloric intake for at least 8 hr. 
 
OGTT** 2-hr PG ≥ 200 mg/dL (11.1 mmol/L)* 
OR 
Random PG ≥ 200 mg/dL (11.1 mmol/L)  
 
PREDIABETES 
HbA1C 5.7 - <6.5% 
OR 
FPG 100 - <126 mg/dL (5.5 - <7.0 mmol/L) 
OR 
OGTT 2-hr PG 140 - <200 mg/dL (7.8 - <11.1 mmol/L) 
 
 
Applicable for a patient with classic symptoms (polyuria, 
polydipsia) or hyperglycemic crisis. 
 
 
 
 
Impaired fasting glucose (IFG) 
 
Impaired glucose tolerance (IGT) 
*In the absence of unequivocal hyperglycemia, this should be confirmed by repeat testing.   
** OGTT with a glucose load containing the equivalent of 1.75 g/kg up to a maximum of 75 g anhydrous 
glucose dissolved in water. 
Abbreviations:  FPG, fasting plasma glucose; HbA1C, hemoglobin A1C; OGTT, oral glucose tolerance 
test; PG, plasma glucose. 
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Table 3.  Complications and cardiovascular risk in youth T2D in the TODAY trial at baseline and follow 
               up.
158, 159, 161
  
 
 
 Prevalence 
Hypertension  
                                   Baseline 11.6% 
                                           End of Study 33.8% 
Microalbuminuria  
                                   Baseline              6.3% 
                                           End of Study 16.6% 
LDL ≥ 130 mg/dl or LLM  
                                 Baseline              4.5% 
                                     Month 36 10.7% 
Triglycerides ≥ 150 mg/dl or LLM  
                                Baseline 21.0% 
                                    Month 36 23.3% 
hsCRP > 0.3 mg/dl  
                               Baseline 41.2% 
                                   Month 36 46.3% 
Retinopathy  
At diabetes duration of 4.9 + 1.5 y            13.7% 
 
LLM: Lipid lowering medication 
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